{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:56:54Z","timestamp":1769500614825,"version":"3.49.0"},"reference-count":3,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the introduction of generic oral isotretinoin there have been discussions around harmonizing the summary of product characteristics of each formulation. As a result of these discussions, a European Directive concerned with the prescribing of oral isotretinoin has been introduced and the FDA (Food and Drugs Administration) has recently implemented new regulations. The aims of this article are to summarize the history of the processes involved, outline the new recommendations and discuss the impact of these changes in clinical practice.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01671.x","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T15:33:27Z","timestamp":1284996807000},"page":"773-776","source":"Crossref","is-referenced-by-count":90,"title":["A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris"],"prefix":"10.1111","volume":"20","author":[{"given":"AM","family":"Layton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HPM","family":"Gollnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CC","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_4_2_2","unstructured":"MHRA. Current problems in pharmacovigilance. Drug Safety Bulletin of the MHRA and CHM. \u2018Tamoxifen and venous thromboembolism\u2019.Oct 2002;28:9."},{"key":"e_1_2_4_3_2","first-page":"404","article-title":"Roaccutane treatment guidelines: results of an international study","volume":"198","author":"Cunliffe WJ","year":"1999","journal-title":"Dermatology"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.17771864.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01671.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01671.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:41:32Z","timestamp":1697046092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01671.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":3,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01671.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01671.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,19]]}}}